Top 3 NASDAQ Stocks Weathering The Coronavirus Storm Right Now

0
885

Now the coronavirus has scrambled the outlook for the economy and Fed policy for at least the first half of 2020 and If the virus continues to disrupt the global economy. The following three stocks look to be must-owns for long-term-minded investors.

China Xiangtai Food Co., Ltd., (NASDAQ: PLIN) through its subsidiaries, engages in the slaughtering, processing, packing, distribution, wholesale, and retail of various fresh pork meat and parts in the People’s Republic of China. The company offers fresh pork and byproducts, as well as beef, lamb, chicken, duck, and rabbit meat. It also provides shredded meat, sliced meat, meat stuffing, pickled meat, lamb and offal, sausage, bacon, steamed and canned meat, breaded chicken, and spicy meat products, as well as chilled and frozen pork. In addition, the company operates supermarket. The company was incorporated in 2018 and is headquartered in Chongqing, the People’s Republic of China.

Gilead Sciences, Inc., (NASDAQ: GILD) a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; and Yuhan Corporation. The company was founded in 1987 and is headquartered in Foster City, California.

Moderna, Inc., (NASDAQ: MRNA) a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and autoimmune and cardiovascular diseases. As of February 14, 2020, the company had 12 programs in clinical trials and a total of 24 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation, as well as the Coalition for Epidemic Preparedness Innovations. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

LEAVE A REPLY

Please enter your comment!
Please enter your name here